Corrigendum to: Feasibility of AI as first reader in the 4-IN-THE-LUNG-RUN lung cancer screening trial: Impact on negative-misclassifications and clinical referral rate, European Journal of Cancer, Volume 216, 5 February 2025, 115214
Anna N.H. Walstra , Harriet L. Lancaster , Marjolein A. Heuvelmans , Carlijn M. van der Aalst , Juul Hubert , Dana Moldovanu , Sytse F. Oudkerk , Daiwei Han , Jan Willem C. Gratama , Mario Silva , Harry J. de Koning , Matthijs Oudkerk
{"title":"Corrigendum to: Feasibility of AI as first reader in the 4-IN-THE-LUNG-RUN lung cancer screening trial: Impact on negative-misclassifications and clinical referral rate, European Journal of Cancer, Volume 216, 5 February 2025, 115214","authors":"Anna N.H. Walstra , Harriet L. Lancaster , Marjolein A. Heuvelmans , Carlijn M. van der Aalst , Juul Hubert , Dana Moldovanu , Sytse F. Oudkerk , Daiwei Han , Jan Willem C. Gratama , Mario Silva , Harry J. de Koning , Matthijs Oudkerk","doi":"10.1016/j.ejca.2025.115294","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"218 ","pages":"Article 115294"},"PeriodicalIF":7.6000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804925000759","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
期刊介绍:
The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.